曲美他嗪治疗老年冠心病伴慢性心力衰竭的疗效观察被引量：3

Observation of the Effects of Trimetazidine in the Aged with Coronary Heart Disease and Heart Failure

导出

摘要目的:探讨曲美他嗪治疗老年冠状动脉粥样硬化性心脏病(简称冠心病)伴慢性心力衰竭的疗效。方法:80例患者随机分为常规治疗组和曲美他嗪组。常规治疗组为应用硝酸酯类、利尿剂、血管紧张转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB),β受体阻滞剂,洋地黄制剂等进行常规治疗;曲美他嗪组为常规治疗组的基础上加用曲美他嗪20mg,每天3次口服,治疗6个月,观察治疗前后患者临床情况及超声心动图指标的变化。结果:治疗后两组心功能均明显改善,心排血量(CO)、每搏量(SV)、射血分数(LVEF)增加,左室舒张末容积(LVEDV)减少(P<0.05,P<0.01),差异有统计学意义,但曲美他嗪组疗效优于常规组,两组比较差异有统计学意义(P<0.05)。结论:曲美他嗪治疗老年冠心病伴慢性心衰安全、有效。 Objective：To evaluate the effects of trimetazidine （TMZ） in patients who suffered from coronary atheroselerosis heart disease complicated with heart failure.Methods：80 selected aged patients were randomly divided into TMZ group and control group.TMZ group received.Trimetazidine （60 mg/d） and routine medications for 6 months,while control group only received routine medications during the same period.Agents administered in control group were Nitrates,Diuretics,Angiotensin converting enzyme inhibitor （ACEI）,Blocker of angiotensin Angiotensin Ⅱ receptor （ARB）,13-receptor antagonist,and digitalis,etc.Observing and comparing the clinical manifestation of patients and echocardiogram outcomes before and after 6 months＇ medication.Results：After 6 months treatment,in both groups cardiac output, stroke volume ejection fraction increased dramatically and left ventricular end diastolic volume decreased （P〈0.05,P〈0.01）,but index improvement in TMZ group were more obvious.There was significant difference between TMZ group and control group （P〈0.05）.Conclusion：TMZ was safe and effective in the aged with coronary heart disease and heart failure.

作者张惠芳牛瑞刚刘金霞刘大成王晨晨刘树静

机构地区北京市房山区第一医院心内科

出处《中国医药导刊》 2010年第7期1194-1195,共2页 Chinese Journal of Medicinal Guide

关键词曲美他嗪冠状动脉粥样硬化性心脏病心力衰竭 Trimetazidine Coronary atherosclerosis heart disease Heart failure

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1曲美他嗪Ⅳ期临床试验协作组.曲美他嗪治疗冠心病合并左心功能不全患者的疗效研究[J].中华心血管病杂志,2005,33(9):793-795. 被引量：123
2慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量：2410
3张之亮,马俊爱.曲美他嗪治疗冠心病心力衰竭的临床观察[J].中国心血管杂志,2006,11(4):301-303. 被引量：38
4赵成宝,王修卫,孙学雨.阿托伐他汀治疗冠心病合并心力衰竭80例分析[J].山东医药,2007,47(26):117-117. 被引量：5
5Abozguia K,ClarkeK,Lee L,et al.Modification of myocardial substrate use as a therapy for heart failure[J].Nat Clin Prac Cardiovasc Med,2006;3(9):490-498.
6Allibardi S,Chierchia SL,Margonato V, et al.Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts[J].Cardiovas Drugs Ther,2001 ;12(6):543-549.
7Killalea SM,Krum H.Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease[J].American Jnumal of Cardiovascular Drugs,2001; 1 (3): 193 -204.
8Kantor PF,Lucien A,Kozak R,et aI.The antianginal drug timetazidine shifts cardiac energe metabolism from fatty acid oxidotion to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoncyl coenzyme A thiolose[J].Circ Res,2000;86(5):580-588.
9Vitale C,Wajngaten M,Sposato B,et aI.Trimetazidine improves ventricular function and quality of life in elderly patients with coronary artery diseasae[J]. Eur Heart 2,2004;25:1814-1821.

二级参考文献13

1费丽萍呼唤风.曲美他嗪对老年冠心病心功能的影响[J].中国现代医药,2003,2:106-106.
2Stanley WC. Changes in cardiac metabolism: a critical step from stable angina to ischemic cardiomyopathy. Eur Heart J Supplements,2001,3 ( Suppl 0) : 02-07.
3Kantor PF, Lucien A, Kozak R, et aL The anfianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res, 2000, 86:580-588.
4Renaud JF. Internal pH, Na^+ , and Ca^++ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther,1988,1:677-686.
5Schiller NB, Shah PM, Crawford M, et aL Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of two-dimensional Echocardiograms. J Am Soc Echocardiogr, 1989, 2:358-367.
6Aussedat J, Ray A, Kay L, et aL Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol, 1993,21 :128-135.
7Brottier L, Baaxt JL, Combe C, et aL Therapeutic value of a cardioprotective agent in patients with severe isehemic cardiomyopathy. Eur Heart J, 1990, 11:207-212.
8Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J, 2001, 22:2164-2170.
9Tereshchenko SN, Drozdov VN, Levchuk NN, el al. Plasma hemostasis and biochemical indices in trimetazidine treatment of patients with chronic heart failure[J]. Ter Arkh, 1998,70:41-43.
10Mody FV, Sigh BN, Mohiuddin IN, el al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischimic myocardial tissue: an evaluation by position emission tomography [J]. Ann J Cardiol, 1998,82 : 42-45.